Skip to main content
. 2022 Aug 4;74(11):1822–1828. doi: 10.1002/acr.24901

Figure 1.

Figure 1

Systemic Lupus Erythematosus Responder Index 4 (SRI‐4) response at 52 weeks in the belimumab systemic lupus erythematosus (SLE) randomized controlled trials (28, 29, 30, 31, 33, 44, 45, 46, 47). The EMBRACE study (asterisk) used the SRI–SLE Disease Activity Index 2000 response, which has modified proteinuria scoring. 95% CI = 95% confidence interval; IV = intravenous; OR = odds ratio; SC = subcutaneous.